About Adamas Pharma
Adamas Pharma is a company based in Emeryville (United States) founded in 2002 was acquired by Supernus Pharmaceuticals in October 2021. Adamas Pharma has raised $68.03 million across 5 funding rounds from investors including Supernus Pharmaceuticals, HHS and Northgate Capital. The company has 142 employees as of December 31, 2021. Adamas Pharma offers products and services including QELBREE.
- Headquarter Emeryville, United States
- Employees 142 as on 31 Dec, 2021
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Adamas Pharmaceuticals, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$68.03 M (USD)
in 5 rounds
-
Latest Funding Round
$1.25 M (USD), Grant
Jul 01, 2012
-
Investors
Supernus Pharmaceuticals
& 5 more
-
Employee Count
142
as on Dec 31, 2021
-
Acquired by
Supernus Pharmaceuticals
(Oct 11, 2021)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Adamas Pharma
Adamas Pharma offers a comprehensive portfolio of products and services, including QELBREE.
Drug for treating central nervous system disorders with prescribing guidelines.
People of Adamas Pharma
Unlock access to complete
Unlock access to complete
Sales and Marketing
160 people
Leadership Team
51 people
Product Management Team
14 people
Senior Team
14 people
Software Development Team
10 people
Operations Team
7 people
Finance and Accounting
7 people
Human Resources and Administration
5 people
Unlock access to complete
Funding Insights of Adamas Pharma
Adamas Pharma has successfully raised a total of $68.03M across 5 strategic funding rounds. The most recent funding activity was a Grant round of $1.25 million completed in July 2012. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Adamas Pharma
Adamas Pharma has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include Supernus Pharmaceuticals, HHS and Northgate Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Mid-stage venture capital investments and support for tech entrepreneurs.
|
Locked | Locked | Locked | |
|
Venture capital investments are managed in technology and healthcare sectors by this firm.
|
Locked | Locked | Locked | |
|
Northgate Capital is engaged in venture capital and private equity investments.
|
Locked | Locked | Locked |
Investor details for Adamas Pharma
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Adamas Pharma
Investment portfolio details for Adamas Pharma
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Adamas Pharma
Detailed financials for Adamas Pharma
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Adamas Pharma Comparisons
Peer comparison for Adamas Pharma
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Adamas Pharma
Detailed competitors of Adamas Pharma
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Adamas Pharma
Complete news archive for Adamas Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Adamas Pharma
Adamas Pharma was founded in 2002 and raised its 1st funding round 3 years after it was founded.
Adamas Pharma is headquartered in Emeryville, United States. It is registered at Emeryville, California, United States.
Neil F. McFarlane is the current CEO of Adamas Pharma.
Adamas Pharma is a funded company, having raised a total of $68.03M across 5 funding rounds to date.
As of Dec 31, 2021, the latest employee count at Adamas Pharma is 142.
Founded in 2002 and based in Emeryville, United States, Adamas Pharma operates as a specialty pharmaceutical company in the central nervous system (CNS) sector. Approved drugs pharmacokinetic profiles are enhanced to develop novel therapeutics, including fixed-dose combinations. The lead candidate, ADS-5102 (amantadine HCl extended-release), is evaluated for levodopa-induced dyskinesia in Parkinsons disease and walking impairment symptoms in multiple sclerosis.
Adamas Pharma offers QELBREE.
Adamas Pharma has 6 investors. Key investors include Supernus Pharmaceuticals, HHS, Northgate Capital, Calibrium, and DAG Ventures.